BMI changes in adolescents treated with bupropion SR for smoking cessation

Lysbeth Floden, Douglas L. Taren, Myra L. Muramoto, Scott Leischow

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation. Methods A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. Results Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. Conclusions A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.

Original languageEnglish (US)
Pages (from-to)26-29
Number of pages4
JournalObesity
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Bupropion
Smoking Cessation
Body Mass Index
Health
Placebos
Pediatric Obesity
Weight Gain
Fear
Obesity
Smoking
Clinical Trials
Weights and Measures

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

BMI changes in adolescents treated with bupropion SR for smoking cessation. / Floden, Lysbeth; Taren, Douglas L.; Muramoto, Myra L.; Leischow, Scott.

In: Obesity, Vol. 24, No. 1, 01.01.2016, p. 26-29.

Research output: Contribution to journalArticle

Floden, Lysbeth ; Taren, Douglas L. ; Muramoto, Myra L. ; Leischow, Scott. / BMI changes in adolescents treated with bupropion SR for smoking cessation. In: Obesity. 2016 ; Vol. 24, No. 1. pp. 26-29.
@article{e69e1ef3aa3a4a18abbb9e13512d783b,
title = "BMI changes in adolescents treated with bupropion SR for smoking cessation",
abstract = "Objective Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation. Methods A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. Results Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. Conclusions A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.",
author = "Lysbeth Floden and Taren, {Douglas L.} and Muramoto, {Myra L.} and Scott Leischow",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/oby.21360",
language = "English (US)",
volume = "24",
pages = "26--29",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - BMI changes in adolescents treated with bupropion SR for smoking cessation

AU - Floden, Lysbeth

AU - Taren, Douglas L.

AU - Muramoto, Myra L.

AU - Leischow, Scott

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation. Methods A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. Results Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. Conclusions A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.

AB - Objective Adolescent overweight and obesity and smoking continue to be very important health challenges because of their lasting effects on overall health. Weight gain after smoking cessation is a barrier to quitting as well as a negative consequence to health. This study reports changes in the body mass index (BMI) z-scores of adolescent smokers participating in a dose-ranging clinical trial of bupropion SR (150 mg/day and 300 mg/day) for smoking cessation. Methods A total of N = 296 adolescent smokers (placebo n = 100, 150 mg/day n = 101, 300 mg/day n = 95) with a BMI z-score of 0.5 (sd: 1.4), 0.5 (sd: 1.3), and 0.5 (sd: 1.2) in the placebo, 150 mg/day, and 300 mg/day groups, respectively, were followed for 6 months. Results Adolescents in the 300 mg/day group had a significant reduction in BMI z-score 6 weeks after quitting (β = -0.16, CI = (-0.29, -0.04), P-value = 0.01). This result was not sustained at the 6-month follow-up. Conclusions A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation. These results are particularly relevant for adolescents who have either overweight or obesity or who have reservations about quitting for fear of gaining weight or BMI.

UR - http://www.scopus.com/inward/record.url?scp=84951146911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951146911&partnerID=8YFLogxK

U2 - 10.1002/oby.21360

DO - 10.1002/oby.21360

M3 - Article

VL - 24

SP - 26

EP - 29

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 1

ER -